Matt Peter Marinkovich, MD
Dermatology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 1 carrier
- Office
- 1
Offices
1 location
Plans that list them
12 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Marinkovich’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence G80575 · Current
Licensed to practise in California · since 1995 · expires 2028-09-30 · Saint Louis University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Original Medicare doctor bills
$2,504
Medicare paid this office $2,504 for 26 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 22 | $2,058 | $82 |
Who their Medicare patients are
26 Original Medicare patients in 2024. Average age 70 · Women 54% · Health risk score 1.48. Sicker patients than 9 in 10 peers; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 54%.
The office billed $12,203, Medicare allowed $3,846 and paid $2,504; for 30 services of 3 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 26 | 30 | 70 | 1.48 | $12,203 | $2,504 |
| 2023 | 30 | 42 | 73 | 1.32 | $14,842 | $3,998 |
| 2022 | 28 | 52 | 75 | 1.02 | $19,514 | $4,446 |
| 2021 | 37 | 95 | 70 | 1.52 | $34,101 | $7,640 |
| 2020 | 35 | 80 | 75 | 1.36 | $30,418 | $5,241 |
| 2019 | 13 | 16 | 74 | 1.79 | $1,741 | $989 |
| 2018 | 30 | 70 | 74 | 1.43 | $6,909 | $4,743 |
| 2017 | 12 | 18 | 69 | 1.00 | $1,925 | $1,170 |
| 2016 | 40 | 81 | 73 | 1.22 | $16,060 | $5,055 |
| 2015 | 43 | 142 | 72 | 1.37 | $25,056 | $8,257 |
| 2014 | 36 | 99 | 72 | 1.34 | $19,854 | $7,083 |
| 2013 | 21 | 64 | 72 | 1.35 | $10,045 | $3,117 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 1 service
| Return visit (30+ min) | 26 | $2,655 | $89 |
2022: 1 service
| Return visit (30+ min) | 24 | $3,482 | $89 |
2021: 1 service
| Return visit (30+ min) | 27 | $6,375 | $87 |
2020: 1 service
| Return visit (30+ min) | 27 | $4,229 | $70 |
2019: 1 service
| Return visit (30+ min) | 12 | $773 | $59 |
2018: 1 service
| Return visit (30+ min) | 26 | $3,867 | $67 |
2016: 1 service
| Return visit (30+ min) | 36 | $3,620 | $61 |
2015: 2 services
| Return visit (30+ min) | 32 | $5,542 | $66 |
| Return visit (30+ min) | 11 | $807 | $67 |
2014: 2 services
| Return visit (30+ min) | 29 | $5,389 | $70 |
| New patient visit (45+ min) | 11 | $1,273 | $116 |
2013: 1 service
| Return visit (30+ min) | 18 | $2,042 | $60 |
Drugs they prescribed that Part D paid
$3,970,285
Pharmacies billed $3,970,285 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
235 generic and 263 brand-name prescriptions · $3,970,285 in drug cost · 37 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Vyjuvek | None | 147 | $3,356,598 | $22,834 |
| Privigen | Immune globulin | 36 | $246,637 | $6,851 |
| Panzyga | Immune globulin | 29 | $150,247 | $5,181 |
| Dupixent | None | 39 | $136,997 | $3,513 |
| Doxycycline Hyclate | None | 31 | $2,189 | $71 |
See all 10 drugs
| Vyjuvek | None | 147 | $3,356,598 | $22,834 |
| Privigen | Immune globulin | 36 | $246,637 | $6,851 |
| Panzyga | Immune globulin | 29 | $150,247 | $5,181 |
| Dupixent | None | 39 | $136,997 | $3,513 |
| Doxycycline Hyclate | None | 31 | $2,189 | $71 |
| Clobetasol Propionate | None | 17 | $1,790 | $105 |
| Prednisone | None | 68 | $527 | $8 |
| Mupirocin | None | 40 | $519 | $13 |
| Dexamethasone | None | 11 | $125 | $11 |
| Methylprednisolone Sodium Succ | None | 11 | $72 | $7 |
Year by year
| 2024 | 498 | 38 | None | 53% | $3,970,285 |
| 2023 | 352 | 32 | None | 47% | $1,893,527 |
| 2022 | 270 | 25 | None | 52% | $673,646 |
| 2021 | 251 | 33 | None | 35% | $547,137 |
| 2020 | 141 | 29 | 0% (0) | 39% | $378,901 |
| 2019 | 264 | 37 | 0% (0) | 7% | $28,873 |
| 2018 | 338 | 33 | 0% (0) | 7% | $33,183 |
| 2017 | 99 | 24 | 0% (0) | None | $11,977 |
| 2016 | 351 | 42 | 0% (0) | 5% | $136,072 |
| 2015 | 330 | 45 | 0% (0) | 11% | $103,693 |
| 2014 | 247 | 30 | None | 4% | $20,695 |
| 2013 | 150 | 20 | 0% (0) | None | $9,929 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 8 drugs
| Vyjuvek | None | 53 | $1,341,906 | $25,319 |
| Privigen | Immune globulin | 39 | $253,410 | $6,498 |
| Gamunex-C | Immune globulin | 21 | $82,425 | $3,925 |
| Dupixent | None | 19 | $75,238 | $3,960 |
| Gammagard Liquid | Immune globulin | 23 | $73,541 | $3,197 |
| Mupirocin | None | 43 | $2,479 | $58 |
| Doxycycline Hyclate | None | 14 | $972 | $69 |
| Prednisone | None | 62 | $685 | $11 |
2022: 6 drugs
| Privigen | Immune globulin | 40 | $261,224 | $6,531 |
| Gammagard Liquid | Immune globulin | 42 | $229,973 | $5,476 |
| Gamunex-C | Immune globulin | 33 | $89,539 | $2,713 |
| Dupixent | None | 24 | $87,112 | $3,630 |
| Doxycycline Hyclate | None | 13 | $1,812 | $139 |
| Prednisone | None | 71 | $396 | $6 |
2021: 5 drugs
| Privigen | Immune globulin | 52 | $389,426 | $7,489 |
| Gammagard Liquid | Immune globulin | 22 | $119,610 | $5,437 |
| Gamunex-C | Immune globulin | 12 | $29,980 | $2,498 |
| Prednisone | None | 72 | $624 | $9 |
| Doxycycline Hyclate | None | 18 | $476 | $26 |
2020: 4 drugs
| Privigen | Immune globulin | 41 | $240,051 | $5,855 |
| Clobetasol Propionate | None | 12 | $850 | $71 |
| Doxycycline Hyclate | None | 12 | $680 | $57 |
| Prednisone | None | 24 | $200 | $8 |
2019: 5 drugs
| Clobetasol Propionate | 28 | $4,230 | $151 |
| Doxycycline Hyclate | 40 | $1,895 | $47 |
| Prednisone | 73 | $733 | $10 |
| Dexamethasone | 33 | $724 | $22 |
| Sulfamethoxazole-Trimethoprim | 15 | $108 | $7 |
2018: 6 drugs
| Clobetasol Propionate | 30 | $11,906 | $397 |
| Doxycycline Hyclate | 38 | $3,026 | $80 |
| Clotrimazole | 31 | $1,770 | $57 |
| Prednisone | 107 | $1,097 | $10 |
| Dexamethasone | 44 | $976 | $22 |
| Sulfamethoxazole-Trimethoprim | 27 | $202 | $7 |
2017: 4 drugs
| Clobetasol Propionate | 11 | $2,472 | $225 |
| Doxycycline Hyclate | 11 | $809 | $74 |
| Dexamethasone | 11 | $373 | $34 |
| Prednisone | 23 | $232 | $10 |
2016: 6 drugs
| Clobetasol Propionate | 31 | $10,353 | $334 |
| Doxycycline Hyclate | 62 | $5,754 | $93 |
| Prednisone | 138 | $1,637 | $12 |
| Mycophenolate Mofetil | 11 | $667 | $61 |
| Triamcinolone Acetonide | 12 | $607 | $51 |
| Sulfamethoxazole-Trimethoprim | 16 | $97 | $6 |
2015: 5 drugs
| Clobetasol Propionate | 41 | $15,347 | $374 |
| Cyclophosphamide | 11 | $9,677 | $880 |
| Doxycycline Hyclate | 36 | $4,792 | $133 |
| Prednisone | 132 | $1,726 | $13 |
| Doxycycline Monohydrate | 20 | $1,119 | $56 |
2014: 4 drugs
| Clobetasol Propionate | 27 | $3,800 | $141 |
| Doxycycline Hyclate | 21 | $3,289 | $157 |
| Prednisone | 116 | $1,387 | $12 |
| Mycophenolate Mofetil | 12 | $1,166 | $97 |
2013: 4 drugs
| Doxycycline Hyclate | 13 | $1,188 | $91 |
| Clotrimazole | 11 | $629 | $57 |
| Prednisone | 42 | $550 | $13 |
| Clobetasol Propionate | 15 | $548 | $37 |
Money from drug and device companies
$20,074 in 2025
| 2025 | 2 | 12 | $17,652 | $20,074 |
| 2024 | 3 | 15 | $14,300 | $15,738 |
| 2023 | 4 | 16 | $19,378 | $22,785 |
| 2022 | 3 | 8 | $11,040 | $11,800 |
| 2021 | 3 | 4 | $6,660 | $6,660 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Krystal Biotech | Vyjuvek | $10,722 | 9 payments
|
| Regeneron Pharmaceuticals | Dupixent | $9,352 | 3 payments
|
See all 12 published payments
| Krystal Biotech | Paid to speak or teach · 2025-07-02 | Vyjuvek | $4,800 |
| Krystal Biotech | Meals · 2025-06-25 | Vyjuvek | $131 |
| Krystal Biotech | Travel · 2025-06-25 | Vyjuvek | $531 |
| Krystal Biotech | Travel · 2025-06-25 | Vyjuvek | $1,249 |
| Krystal Biotech | Travel · 2025-06-25 | Vyjuvek | $353 |
| Krystal Biotech | Meals · 2025-06-20 | Vyjuvek | $19 |
| Krystal Biotech | Meals · 2025-05-16 | Vyjuvek | $17 |
| Krystal Biotech | Paid to speak or teach · 2025-03-06 | Vyjuvek | $3,500 |
| Krystal Biotech | Meals · 2025-02-25 | Vyjuvek | $121 |
| Regeneron Pharmaceuticals | Consulting · 2025-01-31 | Dupixent | $1,336 |
| Regeneron Pharmaceuticals | Consulting · 2025-01-31 | Dupixent | $4,008 |
| Regeneron Pharmaceuticals | Consulting · 2025-01-31 | Dupixent | $4,008 |
See earlier years (2024, 2023, 2022, 2021)
2024: $15,738
| Krystal Biotech | Vyjuvek | $14,480 | 6 payments
|
| Regeneron Pharmaceuticals | Dupixent | $1,228 | 8 payments
|
| E.R. Squibb & Sons L.L.C. | Sotyktu | $30 | 1 payment
|
2023: $22,785
| Krystal Biotech | Vyjuvek | $17,527 | 11 payments
|
| Amryt Pharma Holdings | None | $4,442 | 3 payments
|
| Almirall | None | $800 | 1 payment
|
| Pfizer | Cibinqo | $15 | 1 payment
|
2022: $11,800
| Argenx US | Vyvgart | $5,613 | 4 payments
|
| Amryt Pharma Holdings | None | $4,688 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | Sotyktu | $1,500 | 1 payment
|
2021: $6,660
| Amryt Pharma Holdings | None | $5,490 | 2 payments
|
| Grifols S.A. | None | $600 | 1 payment
|
| Almirall | None | $570 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Krystal Biotech Inc · Open Label Treatment of Beremagene Geperpavec (B-Vec) · 2023 | Their institution | $159,411 |
| ARGENX US, INC. · An Open-Label, Multicenter, Follow-Up Trial of Argx-113-1904 To Evaluate the Safety, Tolerability, and Efficacy of Efgartigimod Ph20 Sc in Patients With Pemphigus (Address+) · 2024 | Their institution | $64,811 |
| ARGENX US, INC. · A Randomized, Double-Blinded, Placebo-Controlled Trial To Investigate the Efficacy, Safety, and Tolerability of Efgartigimod Ph20 Sc in Adult Patients With Pemphigus (Vulgaris Or Foliaceus) (Address) · 2023 | Their institution | $50,781 |
| Regeneron Pharmaceuticals, Inc. · A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid · 2021 | Their institution | $22,259 |
| ARGENX US, INC. · A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study To Investigate the Efficacy and Safety of Efgartigimod Ph20 Sc in Adult Participants With Bullous Pemphigoid · 2023 | Their institution | $18,468 |
| ARGENX US, INC. · An Open-Label, Multicenter, Follow-Up Trial of Argx-113-1904 To Evaluate the Safety, Tolerability, and Efficacy of Efgartigimod Ph20 Sc in Patients With Pemphigus · 2023 | Their institution | $16,143 |
| ARGENX US, INC. · A Randomized, Double-Blinded, Placebo-Controlled Trial To Investigate the Efficacy, Safety, and Tolerability of Efgartigimod Ph20 Sc in Adult Patients With Pemphigus (Vulgaris Or Foliaceus) · 2024 | Their institution | $10,645 |
| Regeneron Pharmaceuticals, Inc. · A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid · 2024 | Their institution | $10,100 |
| ARGENX US, INC. · A Phase 2/3, Randomized, Double-Blinded, Placebo Controlled, Parallel-Group Study To Investigate the Efficacy and Safety of Efgartigimod Ph20 Sc in Adult Participants With Bullous Pemphigoid · 2025 | Their institution | $7,379 |
| ARGENX US, INC. · An Open-Label, Multicenter, Follow-Up Trial of Argx-113-1904 To Evaluate the Safety, Tolerability, and Efficacy of Efgartigimod Ph20 Sc in Patients With Pemphigus (Address+) · 2025 | Their institution | $6,503 |
| Regeneron Pharmaceuticals, Inc. · A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid · 2023 | Their institution | $4,518 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1386734937
- Licence
- CA G80575California G80575: Current · expires 2028-09-30
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X); Federal specialty code 207NI0002X (207NI0002X)
- Mailing address
- 269 Campus Dr # 2145, Stanford, CA, 94305
- NPI first listed
- 2006-10-13
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 269 Campus Dr, Stanford, CA, 94305